139 related articles for article (PubMed ID: 38677041)
21. The importance of integrating diagnostic modalities in patient selection for CRS-HIPEC in colorectal peritoneal metastases.
de Boer NL; Bakkers C; Brandt-Kerkhof AR; de Vries M; Nederend J; Verhoef C; de Hingh IH; Burger JW
Acta Radiol; 2024 Jun; 65(6):525-534. PubMed ID: 38439639
[TBL] [Abstract][Full Text] [Related]
22. Outcomes following synchronous liver resection, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases: A bi-institutional study.
Flood MP; Waters PS; Kelly ME; Shields C; Conneely J; Ramsay R; Michael M; Loveday B; Warrier SK; Mulsow J; Heriot AG
Surg Oncol; 2021 Jun; 37():101553. PubMed ID: 33839444
[TBL] [Abstract][Full Text] [Related]
23. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
24. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
[TBL] [Abstract][Full Text] [Related]
25. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
26. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
27. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Alyami M; Mercier F; Siebert M; Bonnot PE; Laplace N; Villeneuve L; Passot G; Glehen O; Bakrin N; Kepenekian V
Eur J Surg Oncol; 2021 Jan; 47(1):128-133. PubMed ID: 31253545
[TBL] [Abstract][Full Text] [Related]
28. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal metastases from colorectal cancer in the Czech Republic in 2018.
Němec L; Novák J; Mužík J; Krejčí D; Tomášek J; Šefr R; Bartoška P; Antoš F; Dytrych P; Hoskovec D; Levý M; Šimša J; Klos D; Neoral Č
Klin Onkol; 2021; 34(4):278-282. PubMed ID: 34905928
[TBL] [Abstract][Full Text] [Related]
29. Pelvic exenteration combined with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for advanced primary or recurrent colorectal cancer with peritoneal metastases.
Brown KGM; Ansari N; Solomon MJ; Austin KKS; Hamilton AER; Young CJ
Colorectal Dis; 2021 Jan; 23(1):186-191. PubMed ID: 32978813
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study.
Jost E; Mack LA; Sideris L; Dube P; Temple W; Bouchard-Fortier A
Can J Surg; 2020 Feb; 63(1):E71-E79. PubMed ID: 32080999
[TBL] [Abstract][Full Text] [Related]
31. Role of diagnostic laparoscopy in patients with suspicion of colorectal peritoneal metastases to evaluate suitability for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Hentzen JEKR; van der Plas WY; Constansia RDN; Been LB; Hoogwater FJH; van Ginkel RJ; van Dam GM; Hemmer PHJ; Kruijff S
BJS Open; 2019 Dec; 3(6):812-821. PubMed ID: 31832588
[TBL] [Abstract][Full Text] [Related]
32. Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
Clin Interv Aging; 2021; 16():559-568. PubMed ID: 33833505
[TBL] [Abstract][Full Text] [Related]
33. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
34. Treatment and Survival Outcomes for Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study.
Dietz MV; Ziekman MJ; van Kooten JP; Brandt-Kerkhof ARM; van Meerten E; Verhoef C; Madsen EVE
Ann Surg Oncol; 2023 Apr; 30(4):2048-2056. PubMed ID: 36566258
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey.
Steffen T; Putora PM; Hübner M; Gloor B; Lehmann K; Kettelhack C; Adamina M; Peterli R; Schmidt J; Ris F; Glatzer M
Clin Colorectal Cancer; 2019 Dec; 18(4):e335-e342. PubMed ID: 31371166
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer.
Mertens LS; Behrendt MA; Mehta AM; Stokkel L; de Jong J; Boot H; Horenblas S; van der Heijden MS; Moonen LM; Aalbers AGJ; Meinhardt W; van Rhijn BWG
Eur J Surg Oncol; 2019 Sep; 45(9):1740-1744. PubMed ID: 31003721
[TBL] [Abstract][Full Text] [Related]
37. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
[TBL] [Abstract][Full Text] [Related]
38. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O
Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803
[TBL] [Abstract][Full Text] [Related]
39. Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity-Score Analysis.
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
Ann Surg Oncol; 2024 Jan; 31(1):594-604. PubMed ID: 37831280
[TBL] [Abstract][Full Text] [Related]
40. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
